{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:55:32Z","timestamp":1784044532793,"version":"3.55.0"},"reference-count":110,"publisher":"Walter de Gruyter GmbH","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Neurodegenerative diseases comprise a large number of disorders with high impact on human health. Neurodegenerative processes are caused by various etiological factors and differ in their clinical presentation. Neuroinflammation is widely discussed as both a cause and a consequence in the manifestation of these disorders. The interplay between the two entities is considered as a major contributor to the ongoing disease progression. An attentive search and implementation of new and reliable markers specific for the processes of inflammation and degeneration is still needed. YKL-40 is a secreted glycoprotein produced by activated glial cells during neuroinflammation. Neuron-specific enolase (NSE), expressed mainly by neuronal cells, is a long-standing marker for neuronal damage. The aim of this review is to summarize, clarify, and evaluate the potential significance and relationship between YKL-40 and NSE as biomarkers in the monitoring and prognosis of a set of neurological diseases, such as Alzheimer\u2019s disease, Parkinson\u2019s disease, Huntington\u2019s disease, and multiple sclerosis. YKL-40 appears to be a more reliable biomarker in neurological diseases than NSE. The more prominent expression pattern of YKL-40 could be explained with the more obvious involvement of glial cells in pathological processes accompanying each neurodegenerative disease, whereas reduced NSE levels are likely related to low metabolic activity and increased death of neurons.<\/jats:p>","DOI":"10.1515\/revneuro-2019-0100","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:02:56Z","timestamp":1581411776000},"page":"539-553","source":"Crossref","is-referenced-by-count":29,"title":["YKL-40 and neuron-specific enolase in neurodegeneration and neuroinflammation"],"prefix":"10.1515","volume":"31","author":[{"given":"Valentin","family":"Dichev","sequence":"first","affiliation":[{"name":"Department of Medical Biology , Medical University-Plovdiv , Plovdiv 400 , Bulgaria"},{"name":"Research Institute at Medical University-Plovdiv , Plovdiv 4000 , Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kazakova","sequence":"additional","affiliation":[{"name":"Department of Medical Biology , Medical University-Plovdiv , Plovdiv 400 , Bulgaria"},{"name":"Research Institute at Medical University-Plovdiv , Plovdiv 4000 , Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Sarafian","sequence":"additional","affiliation":[{"name":"Department of Medical Biology , Medical University-Plovdiv , Plovdiv 400 , Bulgaria"},{"name":"Research Institute at Medical University-Plovdiv , Plovdiv 4000 , Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"key":"2022062616300729338_j_revneuro-2019-0100_ref_001_w2aab3b7c34b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Abdo, W.F., De Jong, D., Hendriks, J.C., Horstink, M.W., Kremer, B.P., Bloem, B.R., and Verbeek, M.M. (2004). Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson\u2019s disease. Mov. Disord. 19, 571\u2013579.","DOI":"10.1002\/mds.10714"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_002_w2aab3b7c34b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Alcolea, D., Vilaplana, E., Pegueroles, J., Montal, V., S\u00e1nchez-Juan, P., Gonz\u00e1lez-Su\u00e1rez, A., Pozueta, A., Rodr\u00edguez-Rodr\u00edguez, E., Bartr\u00e9s-Faz, D., Vidal-Pi\u00f1eiro, D., et al. (2015). Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer\u2019s disease. Neurobiol. Aging 36, 2018\u20132023.","DOI":"10.1016\/j.neurobiolaging.2015.03.001"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_003_w2aab3b7c34b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Anderson, K.M., Olson, K.E., Estes, K.A., Flanagan, K., Gendelman, H.E., and Mosley, R.L. (2014). Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders. Transl. Neurodegener. 3, 25.","DOI":"10.1186\/2047-9158-3-25"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_004_w2aab3b7c34b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Antonel, A., Mansilla, A., Rami, L., Llad\u00f3, A., Iranzo, A., Olives, J., Balasa, M., S\u00e1nchez-Valle, R., and Molinuevo, J.L. (2014). Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer\u2019s disease. J. Alzheimers Dis. 42, 901\u2013908.","DOI":"10.3233\/JAD-140624"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_005_w2aab3b7c34b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Baldacci, F., Toschi, N., Lista, S., Zetterberg, H., Blennow, K., Kilimann, I., Teipel, S., Cavedo, E., Dos Santos, A.M., Epelbaum, S., et al. (2017). Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer\u2019s disease. Alzheimers Dement. 13, 993\u20131003.","DOI":"10.1016\/j.jalz.2017.01.021"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_006_w2aab3b7c34b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Bano, D., Zanetti, F., Mende, Y., and Nicotera, P. (2011). Neurodegenerative processes in Huntington\u2019s disease. Cell Death Dis. 2, e228.","DOI":"10.1038\/cddis.2011.112"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_007_w2aab3b7c34b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Blennow, K., Wallin, A., and Ekman, R. (1994). Neuron specific enolase in cerebrospinal fluid: a biochemical marker for neuronal degeneration in dementia disorders? J. Neural Transm. Parkinson Dis. Dement. Sect. 8, 183\u2013191.","DOI":"10.1007\/BF02260939"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_009_w2aab3b7c34b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Bonneh-Barkay, D., Wang, G., Starkey, A., Hamilton, R.L., and Wiley, C.A. (2010). In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J. Neuroinflamm. 7, 34.","DOI":"10.1186\/1742-2094-7-34"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_008_w2aab3b7c34b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Bonneh-Barkay, D., Bissel, S.J., Kofler, J., Starkey, A., Wang, G., and Wiley, C.A. (2012). Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol. 22, 530\u2013546.","DOI":"10.1111\/j.1750-3639.2011.00550.x"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_010_w2aab3b7c34b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Brown, K.W., Kynoch, P.A., and Thompson, R.J. (1980). Immunoreactive nervous system of specific enolase (14-3-2 protein) in human serum and cerebrospinal fluid. Clin. Chim. Acta 101, 257\u2013264.","DOI":"10.1016\/0009-8981(80)90251-X"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_011_w2aab3b7c34b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Bussink, A.P., Speijer, D., Aerts, J.M., and Boot, R.G. (2007). Evolution of mammalian chitinase(-like) members of family 18 glycosyl hydrolases. Genetics 177, 959\u2013970.","DOI":"10.1534\/genetics.107.075846"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_012_w2aab3b7c34b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Cant\u00f3, E., Tintor\u00e9, M., Villar, L.M., Costa, C., Nurtdinov, R., \u00c1lvarez-Cerme\u00f1o, J.C., Arrambide, G., Reverter, F., Deisenhammer, F., Hegen, H., et al. (2015). Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain 138, 918\u2013931.","DOI":"10.1093\/brain\/awv017"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_013_w2aab3b7c34b1b6b1ab2b2c13Aa","unstructured":"Carabias, C.S, Gomez, P.A., Panero, I., Eiriz, C., Casta\u00f1o-Le\u00f3n, A.M., Egea, J., Lagares, A. (2019). YKL-40, SAA1, CRP and PCT are promising biomarkers for intracranial severity assessment of traumatic brain injury: relationship with Glasgow Coma Scale and CT volumetry. World Neurosurg. S1878\u2013S8750, 32587\u201332592."},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_014_w2aab3b7c34b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Charil, A. and Filippi, M. (2007). Inflammatory demyelination and neurodegeneration in early multiple sclerosis. J. Neurol. Sci. 259, 7\u201315.","DOI":"10.1016\/j.jns.2006.08.017"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_015_w2aab3b7c34b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Chaves, M.L., Camozzato, A.L., Ferreira, E.D., Piazenski, I., Kochhann, R., Dall\u2019Igna, O., Mazzini, G.S., Souza, D.O., and Portela, L.V. (2010). Serum levels of S100B and NSE proteins in Alzheimer\u2019s disease patients. J. Neuroinflamm. 7, 6.","DOI":"10.1186\/1742-2094-7-6"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_016_w2aab3b7c34b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Chitnis, T. and Weiner, H. (2017). CNS inflammation and neurodegeneration. J. Clin. Invest. 127, 3577\u20133587.","DOI":"10.1172\/JCI90609"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_017_w2aab3b7c34b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Ciancarelli, I., De Amicis, D., Di Massimo, C., Di Scanno, C., Pistarini, C., D\u2019Orazio, N., and Tozzi Ciancarelli, T.M.G. (2014). Peripheral biomarkers of oxidative stress and their limited potential in evaluation of clinical features of Huntington\u2019s patients. Biomarkers 19, 452\u2013456.","DOI":"10.3109\/1354750X.2014.935955"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_018_w2aab3b7c34b1b6b1ab2b2c18Aa","unstructured":"Ciancarelli, I., De Amicis, D., Di Massimo, C., Sandrini, G., Pistarin, C., Carolei, A., and Ciancarelli, T.M.G. (2015). Influence of intensive multifunctional neurorehabilitation on neuronal oxidative damage in patients with Huntington\u2019s disease. Funct. Neurol. 30, 47\u201352."},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_019_w2aab3b7c34b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Comabella, M., Fern\u00e1ndez, M., Martin, R., Rivera-Vallv\u00e9, S., Borr\u00e1s, E., Chiva, C., Juli\u00e0, E., Rovira, A., Cant\u00f3, E., Alvarez-Cerme\u00f1o, J.C., et al. (2010). Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 133, 1082\u20131093.","DOI":"10.1093\/brain\/awq035"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_020_w2aab3b7c34b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Connor, J.R., Dodds, R.A., Emery, J.G., Kirkpatrick, R.B., Rosenberg, M., and Gowen, M. (2000). Human cartilage glycoprotein 39 (HC gp-39) mRNA expression in adult and fetal chondrocytes, osteoblasts and osteocytes by in-situ hybridization. Osteoarthritis Cartil. 8, 87\u201395.","DOI":"10.1053\/joca.1999.0276"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_021_w2aab3b7c34b1b6b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Coulson, D.T., Beyer, N., Quinn, J.G., Brockbank, S., Hellemans, J., Irvine, G.B., Ravid, R., and Johnston, J.A. (2010). BACE1 mRNA expression in Alzheimer\u2019s disease postmortem brain tissue. J. Alzheimers Dis. 22, 1111\u20131122.","DOI":"10.3233\/JAD-2010-101254"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_022_w2aab3b7c34b1b6b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Craig-Schapiro, R., Perrin, R.J., Roe, C.M., Xiong, C., Carter, D., Cairns, N.J., Mintun, M.A., Peskind, E.R., Li, G., Galasko, D.R., et al. (2010). YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer\u2019s disease. Biol. Psychiatry 68, 903\u2013912.","DOI":"10.1016\/j.biopsych.2010.08.025"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_023_w2aab3b7c34b1b6b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Crews, L. and Masliah, E. (2010). Molecular mechanisms of neurodegeneration in Alzheimer\u2019s disease. Hum Mol. Genet. 19, R12\u2013R20.","DOI":"10.1093\/hmg\/ddq160"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_024_w2aab3b7c34b1b6b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"Cunningham, R.T., Morrow, J.I., Johnston, C.F., and Buchanan, K.D. (1994). Serum neurone-specific enolase concentrations in patients with neurological disorders. Clin. Chim. Acta 230, 117\u2013124.","DOI":"10.1016\/0009-8981(94)90264-X"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_025_w2aab3b7c34b1b6b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"Cutler, N.R., Kay, A.D., Marangos, P.J., and Burg, C. (1986). Cerebrospinal fluid neuron-specific enolase is reduced in Alzheimer\u2019s disease. Arch. Neurol. 43, 153\u2013154.","DOI":"10.1001\/archneur.1986.00520020047017"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_026_w2aab3b7c34b1b6b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"Dayalu, P. and Albin, R.L. (2015). Huntington disease: pathogenesis and treatment. Neurol. Clin. 33, 101\u2013114.","DOI":"10.1016\/j.ncl.2014.09.003"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_027_w2aab3b7c34b1b6b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"De Keyser, J., Mostert, J.P., and Koch, M.W. (2008). Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. J. Neurol. Sci. 267, 3\u201316.","DOI":"10.1016\/j.jns.2007.08.044"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_028_w2aab3b7c34b1b6b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Dugger, B.N. and Dickson, D.W. (2017). Pathology of neurodegenerative diseases. Cold Spring Harb. Perspect. Biol. 9, a028035.","DOI":"10.1101\/cshperspect.a028035"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_029_w2aab3b7c34b1b6b1ab2b2c29Aa","doi-asserted-by":"crossref","unstructured":"Francescone, R.A., Scully, S., Faibish, M., Taylor, S.L., Oh, D., Moral, L., Yan, W., Bentley, B., and Shao, R. (2011). Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J. Biol. Chem. 286, 15332\u201315343.","DOI":"10.1074\/jbc.M110.212514"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_030_w2aab3b7c34b1b6b1ab2b2c30Aa","doi-asserted-by":"crossref","unstructured":"Fusetti, F., Pijning, T., Kalk, K.H., Bos, E., and Dijkstra, B.W. (2003). Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J. Biol. Chem. 278, 37753\u201337760.","DOI":"10.1074\/jbc.M303137200"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_031_w2aab3b7c34b1b6b1ab2b2c31Aa","doi-asserted-by":"crossref","unstructured":"Geng, B., Pan, J., Zhao, T., Ji, J., Zhang, C., Che, Y., Yang, J., Shi, H., Li, J., Zhou, H., et al. (2018). Chitinase 3-like 1-CD44 interaction promotes metastasis and epithelial-to-mesenchymal transition through \u03b2-catenin\/Erk\/Akt signaling in gastric cancer. J. Exp. Clin. Cancer Res. 37, 208.","DOI":"10.1186\/s13046-018-0876-2"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_032_w2aab3b7c34b1b6b1ab2b2c32Aa","doi-asserted-by":"crossref","unstructured":"Gispert, J.D., Mont\u00e9, G.C., Falcon, C., Tucholka, A., Rojas, S., S\u00e1nchez-Valle, R., Antonell, A., Llad\u00f3, A., Rami, L., and Molinuevo, J.L. (2016). CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. Neurobiol. Aging 38, 47\u201355.","DOI":"10.1016\/j.neurobiolaging.2015.10.022"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_033_w2aab3b7c34b1b6b1ab2b2c33Aa","doi-asserted-by":"crossref","unstructured":"Glass, C.K., Saijo, K., Winner, B., Marchetto, M.C., and Gage, F.H. (2010). Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918\u2013934.","DOI":"10.1016\/j.cell.2010.02.016"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_034_w2aab3b7c34b1b6b1ab2b2c34Aa","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez, H. and Pacheco, R. (2014). T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases. J. Neuroinflamm. 11, 201.","DOI":"10.1186\/s12974-014-0201-8"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_035_w2aab3b7c34b1b6b1ab2b2c35Aa","unstructured":"Gu, J., Polak, J.M., Tapia, F.J., Marangos, P.J., and Pearse, A.G. (1981). Neuron-specific enolase in the Merkel cells of mammalian skin. The use of specific antibody as a simple and reliable histologic marker. Am. J. Pathol. 104, 63\u201368."},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_036_w2aab3b7c34b1b6b1ab2b2c36Aa","doi-asserted-by":"crossref","unstructured":"Hafner, A., Obermajer, N., and Kos, J. (2012). \u03b3-Enolase C-terminal peptide promotes cell survival and neurite outgrowth by activation of the PI3K\/Akt and MAPK\/ERK signalling pathways. Biochem. J. 443, 439\u2013450.","DOI":"10.1042\/BJ20111351"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_037_w2aab3b7c34b1b6b1ab2b2c37Aa","unstructured":"Haimoto, H., Takahashi, Y., Koshikawa, T., Nagura, H., and Kato, K. (1985). Immunohistochemical localization of \u03b3-enolase in normal human tissues other than nervous and neuroendocrine tissues. Lab. Invest. 52, 257\u2013263."},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_038_w2aab3b7c34b1b6b1ab2b2c38Aa","doi-asserted-by":"crossref","unstructured":"H\u00e5kansson, I., Tisell, A., Cassel, P., Blennow, K., Zetterberg, H., Lundberg, P., Dahle, C., Vrethem, M., and Ernerudh, J. (2017). Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. Eur. J. Neurol. 24, 703\u2013712.","DOI":"10.1111\/ene.13274"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_039_w2aab3b7c34b1b6b1ab2b2c39Aa","doi-asserted-by":"crossref","unstructured":"Hall, S., Surova, Y., \u00d6hrfelt, A., Swedish BioFINDER Study, Blennow, K., Zetterberg, H., and Hansson, O. (2016). Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson\u2019s disease. Mov. Disord. 31, 898\u2013905.","DOI":"10.1002\/mds.26578"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_040_w2aab3b7c34b1b6b1ab2b2c40Aa","doi-asserted-by":"crossref","unstructured":"Haque, A., Polcyn, R., Matzelle, D., and Banik, N.L. (2018). New insights into the role of neuron-specific enolase in neuro-inflammation, neurodegeneration, and neuroprotection. Brain Sci. 8, E33.","DOI":"10.3390\/brainsci8020033"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_041_w2aab3b7c34b1b6b1ab2b2c41Aa","doi-asserted-by":"crossref","unstructured":"He, C.H., Lee, C.G., Dela Cruz, C.S., Lee, C.M., Zhou, Y., Ahangari, F., Ma, B., Herzog, E.L., Rosenberg, S.A., Li, Y., et al. (2013). Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor \u03b12. Cell Rep. 4, 830\u2013841.","DOI":"10.1016\/j.celrep.2013.07.032"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_042_w2aab3b7c34b1b6b1ab2b2c42Aa","doi-asserted-by":"crossref","unstructured":"Hein N\u00e9e Maier, K., K\u00f6hler, A., Diem, R., S\u00e4ttler, M.B., Demmer, I., Lange, P., B\u00e4hr, M., and Otto, M. (2008). Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis. Neurosci. Lett. 436, 72\u201376.","DOI":"10.1016\/j.neulet.2008.02.064"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_043_w2aab3b7c34b1b6b1ab2b2c43Aa","doi-asserted-by":"crossref","unstructured":"Hinsinger, G., Gal\u00e9otti, N., Nabholz, N., Urbach, S., Rigau, V., Demattei, C., Lehmann, S., Camu, W., Labauge, P., Castelnovo, G., et al. (2015). Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Mult. Scler. 21, 1251\u20131261.","DOI":"10.1177\/1352458514561906"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_044_w2aab3b7c34b1b6b1ab2b2c44Aa","doi-asserted-by":"crossref","unstructured":"Houston, D.R., Recklies, A.D., Krupa, J.C., and van Aalten, D.M. (2003). Structure and ligand-induced conformational change of the 39-kDa glycoprotein from human articular chondrocytes. J. Biol. Chem. 278, 30206\u201330212.","DOI":"10.1074\/jbc.M303371200"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_045_w2aab3b7c34b1b6b1ab2b2c45Aa","doi-asserted-by":"crossref","unstructured":"Kaiser, E., Kuzmits, R., Pregant, P., Burghuber, O., and Worofka, W. (1989). Clinical biochemistry of neuron specific enolase. Clin. Chim. Acta 183, 13\u201331.","DOI":"10.1016\/0009-8981(89)90268-4"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_046_w2aab3b7c34b1b6b1ab2b2c46Aa","doi-asserted-by":"crossref","unstructured":"Kato, K., Asai, R., Shimizu, A., Suzuki, F., and Ariyoshi, Y. (1983). Immunoassay of three enolase isozymes in human serum and in blood cells. Clin. Chim. Acta 127, 353\u2013363.","DOI":"10.1016\/0009-8981(83)90162-6"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_047_w2aab3b7c34b1b6b1ab2b2c47Aa","doi-asserted-by":"crossref","unstructured":"Kazakova, M. and Sarafian, V. (2013). YKL-40 in health and disease: a challenge for joint inflammation. Biomed. Rev. 24, 49\u201356.","DOI":"10.14748\/bmr.v24.21"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_048_w2aab3b7c34b1b6b1ab2b2c48Aa","doi-asserted-by":"crossref","unstructured":"Kinney, J.W., Bemiller, S.M., Murtishaw, A.S., Leisgang, A.M., Salazar, A.M., and Lamb, B.T. (2018). Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimers Dement. 4, 575\u2013590.","DOI":"10.1016\/j.trci.2018.06.014"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_049_w2aab3b7c34b1b6b1ab2b2c49Aa","doi-asserted-by":"crossref","unstructured":"Koch, M.W., George, S., Wall, W., Wee Yong, V., and Metz, L.M. (2015). Serum NSE level and disability progression in multiple sclerosis. J. Neurol. Sci. 350, 46\u201350.","DOI":"10.1016\/j.jns.2015.02.009"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_050_w2aab3b7c34b1b6b1ab2b2c50Aa","doi-asserted-by":"crossref","unstructured":"Kognole, A.A. and Payne, C.M. (2017). Inhibition of mammalian glycoprotein YKL-40: identification of the physiological ligand. J. Biol. Chem. 292, 2624\u20132636.","DOI":"10.1074\/jbc.M116.764985"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_051_w2aab3b7c34b1b6b1ab2b2c51Aa","doi-asserted-by":"crossref","unstructured":"Lamers, K.J., Vos, P., Verbeek, M.M., Rosmalen, F., van Geel, W.J., and van Engelen, B.G. (2003). Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Brain Res. Bull. 61, 261\u2013264.","DOI":"10.1016\/S0361-9230(03)00089-3"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_052_w2aab3b7c34b1b6b1ab2b2c52Aa","doi-asserted-by":"crossref","unstructured":"Lautner, R., Mattsson, N., Sch\u00f6ll, M., Augutis, K., Blennow, K., Olsson, B., and Zetterberg, H. (2011). Biomarkers for microglial activation in Alzheimer\u2019s disease. Int. J. Alzheimers Dis. 2011, 939426.","DOI":"10.4061\/2011\/939426"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_053_w2aab3b7c34b1b6b1ab2b2c53Aa","doi-asserted-by":"crossref","unstructured":"Lee, C.G. and Elias, J.A. (2010). Role of breast regression protein-39\/YKL-40 in asthma and allergic responses. Allergy Asthma Immunol. Res. 2, 20\u201327.","DOI":"10.4168\/aair.2010.2.1.20"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_054_w2aab3b7c34b1b6b1ab2b2c54Aa","doi-asserted-by":"crossref","unstructured":"Lee, C.G., Hartl, D., Lee, G.R., Koller, B., Matsuura, H., Da Silva, C.A., Sohn, M.H., Cohn, L., Homer, R.J., Kozhich, A.A., et al. (2009). Role of breast regression protein 39 (BRP-39)\/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J. Exp. Med. 206, 1149\u20131166.","DOI":"10.1084\/jem.20081271"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_055_w2aab3b7c34b1b6b1ab2b2c55Aa","doi-asserted-by":"crossref","unstructured":"Lee, C.M., He, C.H., Nour, A.M., Zhou, Y., Ma, B., Park, J.W., Kim, K.H., Dela Cruz, C., Sharma, L., Nasr, M.L., et al. (2016). IL-13R\u03b12 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses. Nat. Commun. 7, 12752.","DOI":"10.1038\/ncomms12752"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_056_w2aab3b7c34b1b6b1ab2b2c56Aa","doi-asserted-by":"crossref","unstructured":"Leven, M., Douglas, J., Meyers, L., Lee, S., Shin, Y., and Gardner, L. (2014). Neurodegeneration in multiple sclerosis involves multiple pathogenic mechanisms. Degener. Neurol. Neuromusc. Dis. 4, 49\u201363.","DOI":"10.2147\/DNND.S54391"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_057_w2aab3b7c34b1b6b1ab2b2c57Aa","doi-asserted-by":"crossref","unstructured":"Llorens, F., Schmitz, M., Knipper, T., Schmidt, C., Lange, P., Fischer, A., Hermann, P., and Zerr, I. (2017a). Cerebrospinal fluid biomarkers of Alzheimer\u2019s disease show different but partially overlapping profile compared to vascular dementia. Front. Aging Neurosci. 9, 289.","DOI":"10.3389\/fnagi.2017.00289"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_058_w2aab3b7c34b1b6b1ab2b2c58Aa","doi-asserted-by":"crossref","unstructured":"Llorens, F., Th\u00fcne, K., Tahir, W., Kanata, E., Diaz-Lucena, D., Xanthopoulos, K., Kovatsi, E., Pleschka, C., Garcia-Esparcia, P., Schmitz, M., et al. (2017b). YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol. Neurodegener. 12, 83.","DOI":"10.1186\/s13024-017-0226-4"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_059_w2aab3b7c34b1b6b1ab2b2c59Aa","doi-asserted-by":"crossref","unstructured":"Lucas, S.M., Rothwell, N.J., and Gibson, R.M. (2006). The role of inflammation in CNS injury and disease. Br. J. Pharmacol. 147, 232\u2013240.","DOI":"10.1038\/sj.bjp.0706400"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_060_w2aab3b7c34b1b6b1ab2b2c60Aa","doi-asserted-by":"crossref","unstructured":"Magdalinou, N.K., Paterson, R.W., Schott, J.M., Fox, N.C., Mummery, C., Blennow, K., Bhatia, K., Morris, H.R., Giunti, P., Warner, T.T., et al. (2015). A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J. Neurol. Neurosurg. Psychiatry 86, 1240\u20131247.","DOI":"10.1136\/jnnp-2014-309562"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_061_w2aab3b7c34b1b6b1ab2b2c61Aa","doi-asserted-by":"crossref","unstructured":"Malmestr\u00f6m, C., Axelsson, M., Lycke, J., Zetterberg, H., Blennow, K., and Olsson, B. (2014). CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment. J. Neuroimmunol. 269, 87\u201389.","DOI":"10.1016\/j.jneuroim.2014.02.004"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_062_w2aab3b7c34b1b6b1ab2b2c62Aa","doi-asserted-by":"crossref","unstructured":"Ma\u00f1\u00e9-Mart\u00ednez, M.A., Olsson, B., Bau, L., Matas, E., Cobo-Calvo, \u00c1., Andreasson, U., Blennow, K., Romero-Pinel, L., Mart\u00ednez-Y\u00e9lamos, S., and Zetterberg, H. (2016). Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis. J. Neuroimmunol. 299, 112\u2013117.","DOI":"10.1016\/j.jneuroim.2016.08.004"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_063_w2aab3b7c34b1b6b1ab2b2c63Aa","doi-asserted-by":"crossref","unstructured":"Marangos, P.J. and Paul, S.M. (1981). Brain levels of neuron-specific and nonneuronal enolase in Huntington\u2019s disease. J. Neurochem. 37, 1338\u20131340.","DOI":"10.1111\/j.1471-4159.1981.tb04687.x"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_064_w2aab3b7c34b1b6b1ab2b2c64Aa","doi-asserted-by":"crossref","unstructured":"Marangos, P.J. and Schmechel, D.E. (1987). Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu. Rev. Neurosci. 10, 269\u2013295.","DOI":"10.1146\/annurev.ne.10.030187.001413"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_065_w2aab3b7c34b1b6b1ab2b2c65Aa","doi-asserted-by":"crossref","unstructured":"Marangos, P.J., Parma, A.M., and Goodwin, F.K. (1978). Functional properties of neuronal and glial isoenzymes of brain enolase. J. Neurochem. 31, 727\u2013732.","DOI":"10.1111\/j.1471-4159.1978.tb07847.x"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_066_w2aab3b7c34b1b6b1ab2b2c66Aa","doi-asserted-by":"crossref","unstructured":"Marangos, P.J., Schmechel, D.E., Parma, A.M., and Goodwin, F.K. (1980). Developmental profile of neuron-specific (NSE) and non-neuronal (NNE) enolase. Brain Res. 190, 185\u2013193.","DOI":"10.1016\/0006-8993(80)91168-3"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_067_w2aab3b7c34b1b6b1ab2b2c67Aa","doi-asserted-by":"crossref","unstructured":"Nam, S., Jeong, J., Jang, T., Jung, M., Chun, B., Cha, H., and Oak, C. (2016). Neuron-specific enolase as a novel biomarker reflecting tuberculosis activity and treatment response. Kor. J. Intern. Med. 31, 694\u2013702.","DOI":"10.3904\/kjim.2015.407"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_068_w2aab3b7c34b1b6b1ab2b2c68Aa","doi-asserted-by":"crossref","unstructured":"Ngernyuang, N., Yan, W., Schwartz, L.M., Oh, D., Liu, Y.B., Chen, H., and Shao, R. (2018). A heparin binding motif rich in arginine and lysine is the functional domain of YKL-40. Neoplasia 20, 182\u2013192.","DOI":"10.1016\/j.neo.2017.11.011"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_069_w2aab3b7c34b1b6b1ab2b2c69Aa","doi-asserted-by":"crossref","unstructured":"Niemel\u00e4, V., Burman, J., Blennow, K., Zetterberg, H., Larsson, A., and Sundblom, J. (2018). Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington\u2019s disease. PLoS One 13, e0193492.","DOI":"10.1371\/journal.pone.0193492"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_070_w2aab3b7c34b1b6b1ab2b2c70Aa","doi-asserted-by":"crossref","unstructured":"Noelker, C., Hampel, H., and Dodel, R. (2011). Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential. Mol. Diagn. Ther. 15, 83\u2013102.","DOI":"10.1007\/BF03256398"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_071_w2aab3b7c34b1b6b1ab2b2c71Aa","doi-asserted-by":"crossref","unstructured":"Nooijen, P.T., Schoonderwaldt, H.C., Wevers, R.A., Hommes, O.R., and Lamers, K.J. (1997). Neuron-specific enolase, S-100 protein, myelin basic protein and lactate in CSF in dementia. Dement. Geriatr. Cogn. Disord. 8, 169\u2013173.","DOI":"10.1159\/000106627"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_072_w2aab3b7c34b1b6b1ab2b2c72Aa","doi-asserted-by":"crossref","unstructured":"Nordengen, K., Kirsebom, B.E., Henjum, K., Selnes, P., G\u00edslad\u00f3ttir, B., Wettergreen, M., Torsetnes, S.B., Gr\u00f8ntvedt, G.R., Waterloo, K.K., Aarsland, D., et al. (2019). Glial activation and inflammation along the Alzheimer\u2019s disease continuum. J. Neuroinflamm. 16, 46.","DOI":"10.1186\/s12974-019-1399-2"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_073_w2aab3b7c34b1b6b1ab2b2c73Aa","doi-asserted-by":"crossref","unstructured":"Ohno, M., Bauer, P.O., Kida, Y., Sakaguchi, M., Sugahara, Y., and Oyama, F. (2015). Quantitative real-time PCR analysis of YKL-40 and its comparison with mammalian chitinase mRNAs in normal human tissues using a single standard DNA. Int. J. Mol. Sci. 16, 9922\u20139935.","DOI":"10.3390\/ijms16059922"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_074_w2aab3b7c34b1b6b1ab2b2c74Aa","doi-asserted-by":"crossref","unstructured":"\u00d6hrfelt, A., Johansson, P., Wallin, A., Andreasson, U., Zetterberg, H., Blennow, K., and Svensson, J. (2016). Increased cerebrospinal fluid levels of ubiquitin carboxyl-terminal hydrolase L1 in patients with Alzheimer\u2019s disease. Dement. Geriatr. Cogn Dis. Extra. 6, 283\u2013294.","DOI":"10.1159\/000447239"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_075_w2aab3b7c34b1b6b1ab2b2c75Aa","doi-asserted-by":"crossref","unstructured":"Oliva, D., Cal\u00ec, L., Feo, S., and Giallongo, A. (1991). Complete structure of the human gene encoding neuron-specific enolase. Genomics 10, 157\u2013165.","DOI":"10.1016\/0888-7543(91)90496-2"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_076_w2aab3b7c34b1b6b1ab2b2c76Aa","doi-asserted-by":"crossref","unstructured":"Olsson, B., Constantinescu, R., Holmberg, B., Andreasen, N., Blennow, K., and Zetterberg, H. (2013). The glial marker YKL-40 is decreased in synucleinopathies. Mov. Disord. 28, 1882\u20131885.","DOI":"10.1002\/mds.25589"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_077_w2aab3b7c34b1b6b1ab2b2c77Aa","doi-asserted-by":"crossref","unstructured":"\u00d6merhoca, S., Akka\u015f, S.Y., and \u0130\u00e7en, N.K. (2018). Multiple sclerosis: diagnosis and differential diagnosis. Noro Psikiyatr. Ars. 55, S1\u2013S9.","DOI":"10.29399\/npa.23418"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_078_w2aab3b7c34b1b6b1ab2b2c78Aa","unstructured":"Palumbo, B., Siepi, D., Sabalich, I., Tranfaglia, C., and Parnetti, L. (2008). Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer\u2019s disease? Funct. Neurol. 23, 93\u201396."},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_079_w2aab3b7c34b1b6b1ab2b2c79Aa","doi-asserted-by":"crossref","unstructured":"Park, H.Y., Jun, C.D., Jeon, S.J., Choi, S.S., Kim, H.R., Choi, D.B., Kwak, S., Lee, H.S., Cheong, J.S., So, H.S., et al. (2012). Serum YKL-40 levels correlate with infarct volume, stroke severity, and functional outcome in acute ischemic stroke patients. PLoS One 7, e51722.","DOI":"10.1371\/journal.pone.0051722"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_080_w2aab3b7c34b1b6b1ab2b2c80Aa","doi-asserted-by":"crossref","unstructured":"Parnetti, L., Palumbo, B., Cardinali, L., Loreti, F., Chionne, F., Cecchetti, R., and Senin, U. (1995). Cerebrospinal fluid neuron-specific enolase in Alzheimer\u2019s disease and vascular dementia. Neurosci. Lett. 183, 43\u201345.","DOI":"10.1016\/0304-3940(94)11110-5"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_081_w2aab3b7c34b1b6b1ab2b2c81Aa","doi-asserted-by":"crossref","unstructured":"Pouyafar, A., Heydarabad, M.Z., Mahboob, S., Mokhtarzadeh, A., and Rahbarghazi, R. (2018). Angiogenic potential of YKL-40 in the dynamics of tumor niche. Biomed. Pharmacother. 100, 478\u2013485.","DOI":"10.1016\/j.biopha.2018.02.050"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_082_w2aab3b7c34b1b6b1ab2b2c82Aa","doi-asserted-by":"crossref","unstructured":"Prakash, M., Bodas, M., Prakash, D., Nawani, N., Khetmalas, M., Mandal, A., and Eriksson, C. (2013). Diverse pathological implications of YKL-40: answers may lie in \u2018outside-in\u2019 signaling. Cell Signal. 25, 1567\u20131573.","DOI":"10.1016\/j.cellsig.2013.03.016"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_083_w2aab3b7c34b1b6b1ab2b2c83Aa","doi-asserted-by":"crossref","unstructured":"Querol-Vilaseca, M., Colom-Cadena, M., Pegueroles, J., San Mart\u00edn-Paniello, C., Clarimon, J., Belbin, O., Fortea, J., and Lle\u00f3, A. (2017). YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer\u2019s disease and other tauopathies. J. Neuroinflamm. 14, 118.","DOI":"10.1186\/s12974-017-0893-7"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_084_w2aab3b7c34b1b6b1ab2b2c84Aa","doi-asserted-by":"crossref","unstructured":"Recklies, A.D., Ling, H., White, C., and Bernier, S.M. (2005). Inflammatory cytokines induce production of CHI3L1 by articular chondrocytes. J. Biol. Chem. 280, 41213\u201341221.","DOI":"10.1074\/jbc.M510146200"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_085_w2aab3b7c34b1b6b1ab2b2c85Aa","doi-asserted-by":"crossref","unstructured":"Rehli, M., Krause, S.W., and Andreesen, R. (1997). Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 43, 221\u2013225.","DOI":"10.1006\/geno.1997.4778"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_086_w2aab3b7c34b1b6b1ab2b2c86Aa","doi-asserted-by":"crossref","unstructured":"Rehli, M., Niller, H.H., Ammon, C., Langmann, S., Schwarzfischer, L., Andreesen, R., and Krause, S.W. (2003). Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J. Biol. Chem. 278, 44058\u201344067.","DOI":"10.1074\/jbc.M306792200"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_087_w2aab3b7c34b1b6b1ab2b2c87Aa","doi-asserted-by":"crossref","unstructured":"Renkema, G.H., Boot, R.G., Au, F.L., Donker-Koopman, W.E., Strijland, A., Muijsers, A.O., Hrebicek, M., and Aerts, J.M. (1998). Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur. J. Biochem. 251, 504\u2013509.","DOI":"10.1046\/j.1432-1327.1998.2510504.x"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_088_w2aab3b7c34b1b6b1ab2b2c88Aa","doi-asserted-by":"crossref","unstructured":"Ringsholt, M., H\u00f8gdall, E.V., Johansen, J.S., Price, P.A., and Christensen, L.H. (2007). YKL-40 protein expression in normal adult human tissues\u2014an immunohistochemical study. J. Mol. Histol. 38, 33\u201343.","DOI":"10.1007\/s10735-006-9075-0"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_089_w2aab3b7c34b1b6b1ab2b2c89Aa","doi-asserted-by":"crossref","unstructured":"Rodrigues, F.B., Byrne, L.M., McColgan, P., Robertson, N., Tabrizi, S.J., Zetterberg, H., and Wild, E.J. (2016). Cerebrospinal fluid inflammatory biomarkers reflect clinical severity in Huntington\u2019s disease. PLoS One 11, e0163479.","DOI":"10.1371\/journal.pone.0163479"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_090_w2aab3b7c34b1b6b1ab2b2c90Aa","doi-asserted-by":"crossref","unstructured":"Rubinsztein, D.C. (2006). The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443, 780\u2013786.","DOI":"10.1038\/nature05291"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_091_w2aab3b7c34b1b6b1ab2b2c91Aa","doi-asserted-by":"crossref","unstructured":"Schaf, D.V., Tort, A.B., Fricke, D., Schestatsky, P., Portela, L.V., Souza, D.O., and Rieder, C.R. (2005). S100B and NSE serum levels in patients with Parkinson\u2019s disease. Parkinsonism Relat. Disord. 11, 39\u201343.","DOI":"10.1016\/j.parkreldis.2004.07.002"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_092_w2aab3b7c34b1b6b1ab2b2c92Aa","doi-asserted-by":"crossref","unstructured":"Schmechel, D., Marangos, P.J., Zis, A.P., Brightman, M., and Goodwin, F.K. (1978). Brain endolases as specific markers of neuronal and glial cells. Science 199, 313\u2013315.","DOI":"10.1126\/science.339349"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_093_w2aab3b7c34b1b6b1ab2b2c93Aa","doi-asserted-by":"crossref","unstructured":"Schmechel, D.E., Marangos, P.J., Martin, B.M., Winfield, S., Burkhart, D.S., Roses, A.D., and Ginns, E.I. (1987). Localization of neuron-specific enolase (NSE) mRNA in human brain. Neurosci. Lett. 76, 233\u2013238.","DOI":"10.1016\/0304-3940(87)90721-X"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_094_w2aab3b7c34b1b6b1ab2b2c94Aa","doi-asserted-by":"crossref","unstructured":"Schmidt, F.M., Mergl, R., Stach, B., Jahn, I., Gertz, H.J., and Sch\u00f6nknecht, P. (2014). Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE) in Alzheimer\u2019s disease. Neurosci. Lett. 570, 81\u201385.","DOI":"10.1016\/j.neulet.2014.04.007"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_095_w2aab3b7c34b1b6b1ab2b2c95Aa","doi-asserted-by":"crossref","unstructured":"Shao, R., Hamel, K., Petersen, L., Cao, Q.J., Arenas, R.B., Bigelow, C., Bentley, B., and Yan, W. (2009). YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 28, 4456\u20134468.","DOI":"10.1038\/onc.2009.292"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_096_w2aab3b7c34b1b6b1ab2b2c96Aa","doi-asserted-by":"crossref","unstructured":"Shao, R., Taylor, S.L., Oh, D.S., and Schwartz, L.M. (2015). Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization. Oncotarget 6, 40507\u201340518.","DOI":"10.18632\/oncotarget.5943"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_097_w2aab3b7c34b1b6b1ab2b2c97Aa","doi-asserted-by":"crossref","unstructured":"Sladkova, V., Mare\u0161, J., Lubenova, B., Zapletalova, J., Stejskal, D., Hlustik, P., and Kanovsky, P. (2011). Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome. Neurol. Res. 33, 415\u2013420.","DOI":"10.1179\/016164110X12816242542535"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_098_w2aab3b7c34b1b6b1ab2b2c98Aa","doi-asserted-by":"crossref","unstructured":"Smith, J.A., Das, A., Ray, S.K., and Banik, N.L. (2012). Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res. Bull. 87, 10\u201320.","DOI":"10.1016\/j.brainresbull.2011.10.004"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_099_w2aab3b7c34b1b6b1ab2b2c99Aa","doi-asserted-by":"crossref","unstructured":"Spangenberg, E.E. and Green, K.N. (2017). Inflammation in Alzheimer\u2019s disease: lessons learned from microglia-depletion models. Brain Behav. Immun. 61, 1\u201311.","DOI":"10.1016\/j.bbi.2016.07.003"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_100_w2aab3b7c34b1b6b1ab2b2d100Aa","doi-asserted-by":"crossref","unstructured":"Strimbu, K. and Tavel, J.A. (2010). What are biomarkers? Curr. Opin. HIV AIDS 5, 463\u2013466.","DOI":"10.1097\/COH.0b013e32833ed177"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_101_w2aab3b7c34b1b6b1ab2b2d101Aa","doi-asserted-by":"crossref","unstructured":"Sulkava, R., Viinikka, L., Erkinjuntti, T., and Roine, R. (1988). Cerebrospinal fluid neuron-specific enolase is decreased in multi-infarct dementia, but unchanged in Alzheimer\u2019s disease. J. Neurol. Neurosurg. Psychiatry 51, 549\u2013551.","DOI":"10.1136\/jnnp.51.4.549"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_102_w2aab3b7c34b1b6b1ab2b2d102Aa","doi-asserted-by":"crossref","unstructured":"Villar-Piqu\u00e9, A., Schmitz, M., Hermann, P., Goebel, S., Bunck, T., Varges, D., Ferrer, I., Riggert, J., Llorens, F., and Zerr, I. (2019). Plasma YKL-40 in the spectrum of neurodegenerative dementia. J. Neuroinflamm. 16, 145.","DOI":"10.1186\/s12974-019-1531-3"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_103_w2aab3b7c34b1b6b1ab2b2d103Aa","doi-asserted-by":"crossref","unstructured":"Vinther-Jensen, T., Budtz-J\u00f8rgensen, E., Simonsen, A.H., Nielsen, J.E., and Hjermind, L.E. (2014). YKL-40 in cerebrospinal fluid in Huntington\u2019s disease\u2014a role in pathology or a nonspecific response to inflammation? Parkinsonism Relat. Disord. 20, 1301\u20131303.","DOI":"10.1016\/j.parkreldis.2014.08.011"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_104_w2aab3b7c34b1b6b1ab2b2d104Aa","doi-asserted-by":"crossref","unstructured":"Vizin, T. and Kos, J. (2015). Gamma-enolase: a well-known tumour marker, with a less-known role in cancer. Radiol. Oncol. 49, 217\u2013226.","DOI":"10.1515\/raon-2015-0035"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_105_w2aab3b7c34b1b6b1ab2b2d105Aa","unstructured":"Wenning, G.K. and Quinn, N.P. (1997). Parkinsonism. Multiple system atrophy. Baillieres Clin. Neurol. 6, 187\u2013204."},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_106_w2aab3b7c34b1b6b1ab2b2d106Aa","doi-asserted-by":"crossref","unstructured":"Wennstr\u00f6m, M., Surova, Y., Hall, S., Nilsson, C., Minthon, L., Hansson, O., and Nielsen, H.M. (2015). The inflammatory marker YKL-40 is elevated in cerebrospinal fluid from patients with Alzheimer\u2019s but not Parkinson\u2019s disease or dementia with Lewy bodies. PLoS One 10, e0135458.","DOI":"10.1371\/journal.pone.0135458"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_107_w2aab3b7c34b1b6b1ab2b2d107Aa","doi-asserted-by":"crossref","unstructured":"Yamanaka, K. and Kominea, O. (2018). The multi-dimensional roles of astrocytes in ALS. Neurosci. Res. 126, 31\u201338.","DOI":"10.1016\/j.neures.2017.09.011"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_108_w2aab3b7c34b1b6b1ab2b2d108Aa","doi-asserted-by":"crossref","unstructured":"Zeng, X.-S., Geng, W.-S., Jia, J.-J., Chen, L., and Zhang, P.P. (2018). Cellular and molecular basis of neurodegeneration in Parkinson disease. Front. Aging Neurosci. 10, 109.","DOI":"10.3389\/fnagi.2018.00109"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_109_w2aab3b7c34b1b6b1ab2b2d109Aa","doi-asserted-by":"crossref","unstructured":"Zhou, Y., He, C.H., Herzog, E.L., Peng, X., Lee, C.M., Nguyen, T.H., Gulati, M., Gochuico, B.R., Gahl, W.A., Slade, M.L., et al. (2015). Chitinase 3-like-1 and its receptors in Hermansky-Pudlak syndrome-associated lung disease. J. Clin. Invest. 125, 3178\u20133192.","DOI":"10.1172\/JCI79792"},{"key":"2022062616300729338_j_revneuro-2019-0100_ref_110_w2aab3b7c34b1b6b1ab2b2d110Aa","doi-asserted-by":"crossref","unstructured":"Zhou, Y., He, C.H., Yang, D.S., Nguyen, T., Cao, Y., Kamle, S., Lee, C.M., Gochuico, B.R., Gahl, W.A., Shea, B.S., et al. (2018). Galectin-3 interacts with the CHI3L1 axis and contributes to Hermansky-Pudlak syndrome lung disease. J. Immunol. 200, 2140\u20132153.","DOI":"10.4049\/jimmunol.1701442"}],"container-title":["Reviews in the Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/revneuro\/31\/5\/article-p539.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/revneuro-2019-0100\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/revneuro-2019-0100\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T16:40:46Z","timestamp":1656261646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/revneuro-2019-0100\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":110,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,3,3]]},"published-print":{"date-parts":[[2020,7,28]]}},"alternative-id":["10.1515\/revneuro-2019-0100"],"URL":"https:\/\/doi.org\/10.1515\/revneuro-2019-0100","relation":{},"ISSN":["2191-0200","0334-1763"],"issn-type":[{"value":"2191-0200","type":"electronic"},{"value":"0334-1763","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,11]]}}}